As antisense drugs advance through clinical trials, is a “data gap” emerging between biotechnology companies, regulatory agencies, and academia?
This is a preview of subscription content, log in via an institution to check access.
Rights and permissions
About this article
Cite this article
Antisense '97: A roundtable on the state of the industry. Nat Biotechnol 15, 519–524 (1997). https://doi.org/10.1038/nbt0697-519
Issue Date:
DOI: https://doi.org/10.1038/nbt0697-519
- Springer Nature America, Inc.